Fennec with everyone. I role its to morning, the this look growth organization Robert, lead forward and Thank I'm new incredibly working good and efforts. excited continued direct through team to this you, in to
like to pediatric be a critical as Fennec, that Rosty needed a profound oncology on would the know, was therapy at leadership impact, XXXX. and since only patients. irreversible thank his I the hearing not much of lifelong but can He's to I bringing these which been risk for for dedication myself, to introduce Before success you population loss,
at we're able to benefit next and we be of knowledge enter continue pleased Fennec, we the into as behalf experience Rosty's chapter. On everyone from to will
years. me, talk generating a XX oncology Sigma-Tau, commercial tenure little in company's me Pharma, Let product Shire in bit where years-or-so those U.S. about over I for the responsible and my companies billions last was spans organizations multiple EUSA in Baxalta, like the franchises, managing and portfolios the with revenues
to clear it's fill passion incredible evident, talent to here, forward. to organization needs markets confident oncology pool have our relevant I that specific to of we commercializing gaps As any week I'm a work and last expertise of pediatric lot and and Fennec. at drive access an with spent that are here specifically my Robert mentioned, team to the are Fennec the interactions products oncology through experience at very my that where first time we me address can early about.
From Fennec's have together, PEDMARK and and community any I'm dedication, passionate in I
second our call. all outlined results, release this morning earlier press quarter to turning Now our before in XXXX of earnings which were issued financial the
to we abroad, Australia Zealand. New Europe, with and We commercial discuss PEDMARK following executed Norgine the and the will in March efforts commercialize ongoing U.S. licensing also in in exclusive PEDMARQSI we're with launch progress announcement making agreement and
on the office and the approval SEDAR the safety stakeholder that engagement to several quarter. professional build delivered of key second FDA new that revenues a at milestones staff the affairs In by patient PEDMARK's $X.X drugs achieved believe recently added the communication FDA off May, enable will of and to We second there quarter, accelerate PEDMARK that we were achieved net -- us page. million. In issued access
Now it address with to issue. continues Fennec the is diligently work risks. that pose FDA health this to potential substitutions clear
were the Advantage, During commercial outlining FDA Medicaid notifications recipients payers. included quarter, administrative managed Medicare second the and Payer sent non-substitution contractors, Medicare status.
all systems, more including health oncology included state community-based hospitals; oncology the societies; top These hospital XXX recipients owned. than or Provider XX and practices. are children's
X, Additionally, as it of fully was resolved we specify April CMS, our issued, J-Code with PEDMARK. to amending and this
replaced importance, we this of that removed this uptake patient to guidelines are with ototoxicity years The will PEDMARK wording as and within believe that and Now the population platinum. access PEDMARK. of change up recently two, is move cisplatin and XX improve to guidelines broader the to quarters prevention for age; allows updated modified continue and their believe great seeing we pediatric-specific the forward.
Further, We NCCN patients we application. allowed AYA for affected a
that the Now submitted quarter. end anticipate compendia this drug and guidelines remaining of by be AYA we've modified, updates been to NCCN data the to packages the will compendia have clinical targeted completed PEDMARK the these that
into milestones achieved, remain and confident about for the to the marketplace We're first half foundation put recent changes the these all we achieve the for that in our ability months with to XX So these launch. optimistic place the given we second year of excited and long-term navigate Fennec, objectives. through of
infusion within and to steps depend adults. and hospitals the successfully patients ability Our forward institutions and NCCN largely next older community to few guidelines with the with outlook our for adolescents these to key label for on our young continue outpatient the these centers setting and target treat positive quarters make will
within to our ovarian label. significantly our this treat population.
Recently, community do include: the neck pediatric population, we within as population administered in patients that AYA segment activities plans hospital so force fall testicular that believe to to this treated into there the that have tumor are We cancer. has such sales compared are cancer patients and expanded this their Our types and centers head including inpatient more now and cancer,
Cross Blue as United Caremark. Shield, We have such Blue process successfully with managed plans major the reimbursement and health
into diligently takes work continue We it accommodate to cisplatin the our reach hours to after center that is X time which administer extend PEDMARK, to infusion. with to managers infusion senior hours
with in Specialty -- help Orsini's patient high-touch provide off partnering that We personalized access recent care. will these model to continue centers through Orsini to care care PEDMARK high-touch model build success Pharmacy our patients
Now Europe, Zealand, PEDMARQSI track. Australia to and regarding commercialize progress on our with continue in launch territories XXXX, QX New partnership targeted late to efforts this Norgine our remains these and and
million approximately to the As in regulatory and of responsible Fennec of the of a the royalties upfront reminder, hold consideration $XX.X potential on commercial $XXX will agreement, of commercialization net and under in up be next the million approximately territories activities milestone territories. to marketing and sales Germany and license launch in licensing The PEDMARQSI the be major these these additional XXXX. QX payments tiered license terms of for received territories all the evaluated in up will all authorizations in will license mid-XXs.
Norgine milestone after in these
partnership this an at communicated, cisplatin-induced for achieving previously across our PEDMARQSI we've ototoxicity. globe expanding suffering As who represents risk step from are mission of patients of important the to
in of experienced These many participation providing partner terms payment, with a to launch benefits, sheet, PEDMARQSI and further an economic ex-U.S. us the balance provided important meaningful these solidifying success PEDMARQSI attractive including in upfront our successfully terms, territories. licensed an
taking including plans. promising steps our see we the to commercial closing, the PEDMARK, for on continue we're opportunities in educate with marketplace to So executing along
our seeing We actions in to are the months. of the benefits looking coming forward
back the going to for Robert So financials to with over turn the that, to the I'm call over quarter. go
